Abstract: One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.
Type:
Grant
Filed:
April 22, 2014
Date of Patent:
October 20, 2015
Assignee:
GENZYME CORPORATION
Inventors:
W. Scott McDougal, Dianne E. Sacco, Alexander Schwarz, Jean-Marie Vogel
Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
Abstract: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.
Type:
Grant
Filed:
January 26, 2010
Date of Patent:
September 29, 2015
Assignees:
University of Miami, The General Hospital Corporation
Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
Abstract: With regard to compositions derived from active ingredients and other additives in medical, food and industrial fields, there have been problems that the active ingredients cannot be uniformly mixed, and that the active ingredients become segregated and lose uniformity as the active ingredients undergo transport, input, and filling processes. There is provided a cellulose powder which improves the uniformity of compositions containing active ingredients or other additives to prevent segregation of the active ingredients, wherein the cellulose powder contains cellulose I type crystals, has an average particle diameter of less than 30 ?m, a powder density of 0.1 to 0.45 g/cm3, a tapping density of 0.1 to 0.5 g/cm3, a repose angle of 35 to 50°, a specific surface of more than or equal to 0.1 m2/g and less than 20 m2/g, an internal friction angle of 36 to 42°, and is a cellulose powder including a secondary flocculation structure in which primary particles are flocculated.
Abstract: The present invention relates to a process of enriching one target compound from a liquid, which process comprises at least one step of isolation performed by differentially partitioning between two aqueous phases. In the present invention the phases are formed by adding a thermally responsive, self-associating (i.e. clouding) hydrophilic polymer, and if needed some additional salts, to an aqueous biotechnical solution (such as a fermentation sample or bioseparation process stream) under thermal and other conditions where the solution separates into a one polymer, two-phase system with one phase enriched in the polymer. The target compound is to be found in the phase not enriched in the polymer, while a significant though varying percentage of contaminants may differentially partition to the phase interface or the polymer enriched phase.
Type:
Grant
Filed:
January 7, 2010
Date of Patent:
August 25, 2015
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
James Van Alstine, Jamil Shanagar, Rolf Hjorth, Martin Hall, Camilla Estmer Nilsson
Abstract: A bioresorbable porous film, including a blend mixture of polylactic acid and at least two kinds of polyethylene glycol, wherein the at least two kinds of polyethylene glycol include a first polyethylene glycol, which is in a solid form under ambient temperature and atmospheric pressure, and a second polyethylene glycol, which is in a liquid form under ambient temperature and atmospheric pressure is provided. The film has a porosity of 10%-90%.
Type:
Grant
Filed:
April 25, 2013
Date of Patent:
August 18, 2015
Assignee:
INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Abstract: Described herein are methods for isolating and purifying antibodies from a sample matrix. One aspect of the present disclosure is directed to viral reduction/inactivation of samples generated in the various steps of antibody purification. In a particular aspect, methods herein employ an acidification step followed by one or more chromatography steps. The chromatography steps can include one or more of the following chromatographic procedures: ion exchange chromatography, affinity chromatography, and hydrophobic interaction chromatography.
Abstract: Methods and kits for regenerating antibody binding resins are provided. In some embodiments the methods include a first step of washing an antibody binding resin with a reducing solution, followed by a second step of washing the antibody binding resin with a chaotropic solution.
Abstract: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
Abstract: The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product.
Type:
Grant
Filed:
August 2, 2012
Date of Patent:
August 4, 2015
Assignee:
EMD Millipore Corporation
Inventors:
Nanying Bian, Christopher Gillespie, Matthew T. Stone, Mikhail Kozlov, Jie Chen, Martin Siwak
Abstract: The present document relates to a manufacturing method for pH-sensitive graft polymer micelles and a polymer micelle-type pharmaceutical composition containing the graft copolymer. The pH-sensitive graft copolymer micelles are usable as various markers and contrast agents for various molecular images for the diagnosis and treatment of diseases and a carrier for delivery of various medicines according to disease. The pH-sensitive graft copolymer forms micelles that can be used in target-oriented diagnosis and medicine release according to changes in the pH of a body. The polymer micelles are provided by inducing a graft copolymer of poly (?-amino ester) compounds which has a solubility in water depending on pH but is incapable of forming the micelles due to a self-assembly phenomenon, and hydrophilic poly(ethylene glycol) compounds.
Type:
Grant
Filed:
April 9, 2010
Date of Patent:
July 14, 2015
Assignee:
RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
Inventors:
Doo Sung Lee, Min Sang Kim, Bong Sup Kim
Abstract: Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.
Abstract: Provided herein are methods and compositions, including pharmaceutical compositions, for stimulating liver regeneration after partial hepatectomy, massive liver resection and toxic injury, or following liver transplantation, including small-for-size liver transplantation, by inhibiting activation of complement.
Type:
Grant
Filed:
July 2, 2010
Date of Patent:
June 30, 2015
Assignee:
MUSC Foundation for Research Development
Inventors:
Stephen Tomlinson, Songqing He, Carl Atkinson
Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.
Type:
Grant
Filed:
April 24, 2014
Date of Patent:
June 30, 2015
Assignee:
Genzyme Corporation
Inventors:
Pradeep K. Dhal, David J. Harris, Stephen Randall Holmes-Farley, Chad C. Huval, Vitaly Nivorozhkin, Bruce Shutts
Abstract: The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders.
Abstract: A plaster containing an active ingredient for the transdermal administration of a pharmaceutical active ingredient, having a removable protective film and an adhesive layer. The plaster includes at least one compound that is contained in the adhesive layer or lies adjacent the adhesive layer between the adhesive layer and the removable protective film and that can be applied to the skin to at least reduce skin irritation.
Type:
Grant
Filed:
August 25, 2006
Date of Patent:
June 30, 2015
Assignee:
Gruenenthal GmbH
Inventors:
Heinrich Kugelmann, Johannes Bartholomäus, Rasoul Sedaghat Kerdar
Abstract: An object of the present invention is to provide a method for removing even small viruses from a high concentration monoclonal antibody solution using a membrane, and thus for recovering the antibody within a short time at high yield in the form of a filtrate. The present invention provides a method for producing a preparation containing a monoclonal antibody, which comprises a step of removing viruses by filtering viruses in a monoclonal antibody solution using a virus-removing membrane, wherein (1) the monomer content of the monoclonal antibody accounts for 90% or more; (2) the monoclonal antibody concentration in the monoclonal antibody solution ranges from 20 mg/ml to 100 mg/ml; (3) the monoclonal antibody solution contains at least a basic amino acid; and (4) the parvovirus removal rate of the virus-removing membrane satisfies the following conditions: LRV (Log Reduction Value: logarithmic reduction value)?4.
Abstract: There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
June 9, 2015
Assignee:
Agency for Science, Technology and Research
Inventors:
Karthikeyan Narayanan, Andrew Chwee Aun Wan, Jackie Y. Ying, Nandanan Erathodiyil